Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amgen and Biovitrum expand type 2 diabetes and metabolic disease agreement

Feb. 15, 2006

Cangene awarded funding to develop PEG-GM-CSF for acute radiation syndrome

Feb. 15, 2006

Takeda granted rights for Hematide in Japan

Feb. 15, 2006

Progressive weight loss observed in pramlintide dose-ranging study

Feb. 14, 2006

Zelos completes enrollment in two phase II studies of Ostabolin-C

Feb. 14, 2006

Targeting FXR for hyperglycemia and hyperlipidemia in diabetes

Feb. 14, 2006

Novel agents for endocrine-related disorders reported in recent patent literature

Feb. 10, 2006

MF-101 studied in phase II trial for treatment of menopausal symptoms

Feb. 10, 2006

Phase I trial investigates APD-668 for type 2 diabetes

Feb. 10, 2006

Potent targeting of c-Fos enhances the antiosteogenic activity of new vitamin D analogues

Feb. 9, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model
BioWorld Science
Camp4 Therapeutics Corp. has highlighted new preclinical data for CMP-002, the company’s lead investigational antisense oligonucleotide (ASO) therapeutic...